Published online May 26, 2025. doi: 10.4252/wjsc.v17.i5.103100
Revised: February 17, 2025
Accepted: April 16, 2025
Published online: May 26, 2025
Processing time: 199 Days and 18.6 Hours
Retinal pigment epithelium (RPE) dysfunction is involved in the advancement of numerous degenerative retinal illnesses, such as age-related macular degeneration and hereditary retinal abnormalities. Transplantation of RPE produced from stem cells has emerged as a promising therapeutic strategy to restore retinal function and prevent vision loss. However, other obstacles impede its clinical application, including immunological rejection, cell viability, functional integration, and the necessity for consistent differentiation techniques. This review offers a thorough examination of the molecular processes regulating RPE integrity, investigates recent progress in stem cell-derived RPE therapeutics, and addresses significant challenges to their broad implementation. Furthermore, we emphasize prospective avenues intended to enhance the safety, efficacy, and enduring success of RPE transplantation in clinical environments.
Core Tip: There has been significant progress in research on the retinal pigment epithelium (RPE), with a particular focus on stem cell therapies and molecular discoveries that have the potential to treat retinopathies. The RPE is crucial for vision and for eye health. Studies have demonstrated the potential of using stem cell-derived RPE to cure retinopathies in their early stages. Understanding the molecular and genetic mechanisms involved in RPE development and differentiation are fundamental in identifying novel therapeutic approaches.